Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers

This article demonstrates that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for “risk” or “volume”.

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abiraterone or enzalutamide)

Videos

Prostate-Specific Membrane Antigen (PSMA) in primary cancer and recurrent disease

Watch now

Relapse after local treatment: is everything so clear in 2019?

Watch now

What urologists need to know about radiotherapy

Watch now

EAU Guidelines on Prostate Cancer

This project was made possible by an educational grant of Janssen, the Pharmaceutical Companies of Johnson & Johnson

Articles

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens

Risk of metastatic disease on 68Ga‐PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer

Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study

EAU Edu Platform on Prostate Cancer

Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Upcoming events

8th Meeting of the EAU Section of Urological Imaging (ESUI19)

11th European Multidisciplinary Congress on Urological Cancers (EMUC19)

ESU course on Prostate cancer, kidney and reconstruction during the national congress of the Iraqi Urological Association (ESU-Baghdad19)

Videos

Prostate-Specific Membrane Antigen (PSMA) in primary cancer and recurrent disease

Relapse after local treatment: is everything so clear in 2019?

What urologists need to know about radiotherapy

Pathology update

EAU Guidelines on Prostate Cancer

Follow us

Articles

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens

Risk of metastatic disease on 68Ga‐PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer

Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study